Nicotinic Cholinergic Modulation: Galantamine as a Prototype
نویسندگان
چکیده
منابع مشابه
Behavioral/Systems/Cognitive 4* Nicotinic Receptors in preBötzinger Complex Mediate Cholinergic/Nicotinic Modulation of Respiratory Rhythm
Acetylcholine and nicotine can modulate respiratory patterns by acting on nicotinic acetylcholine receptors (nAChRs) in the preBötzinger complex (preBötC). To further explore the molecular composition of these nAChRs, we studied a knock-in mouse strain with a leucine-to-alanine mutation in the M2 pore-lining region (L9 A) of the nAChR 4 subunit; this mutation renders 4-containing receptors hype...
متن کاملCharacterization of nicotinic cholinergic receptors
Objective: To characterize nicotinic cholinergic receptors (cholinoceptors) in frog rectus abdominis and mouse esophagus. Material and Methods: Isolated preparations of mouse esophagus and frog rectus abdominis were separately mounted in organ baths filled with Krebs and Ringer solutions respectively. The organ bath medium was continuously gassed with 95% O 2 and 5% CO 2 and the temperature was...
متن کاملGalantamine Effect on Tularemia Pathogenesis in a BALB/c Mouse Model
Background: Galantamine is a drug used for the treatment of Alzheimer’s disease and some other cognitive disorders. It is an inhibitor of acetylcholinesterase however, interaction with nicotinic acetylcholine receptors has also been reported. Owing to the significant role of cholinergic anti-inflammatory pathways in neuro-immunomodulation, we decided to examine the effect of galantamine on tula...
متن کاملGalantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning.
Classical eyeblink conditioning is a well-characterized model paradigm that engages the septohippocampal cholinergic system. This form of associative learning is impaired in normal aging and severely disrupted in Alzheimer's disease (AD). Some nicotinic cholinergic receptor subtypes are lost in AD, making the use of nicotinic allosterically potentiating ligands a promising therapeutic strategy....
متن کاملCompetitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors.
Galantamine, a drug used to treat Alzheimer's disease, is a nicotinic allosteric potentiating ligand, and kynurenic acid (KYNA), a neuroactive metabolite of the kynurenine pathway, is an endogenous noncompetitive inhibitor of alpha7* nicotinic receptors (nAChRs) [the asterisk next to the nAChR subunit is intended to indicate that the exact subunit composition of the receptor is not known (Pharm...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: CNS Drug Reviews
سال: 2006
ISSN: 1080-563X
DOI: 10.1111/j.1527-3458.2002.tb00237.x